Report Detail
JP Morgan 2019 - Conference Review
The 37th annual JP Morgan Healthcare Conference took place in San Francisco, CA from January 7-10, 2019. A list of events and catalysts that were announced or updated at the conference are included in this report, as well as key points from the company presentations, and a summary of the State of the Industry Briefing on cell and gene therapies, which was also held in San Francisco, CA.
Highlights from the company presentations are included for:
Mega Cap
- Novartis (NVS)
- Pfizer (PFE)
- Merck KGaA (MKGAY)
Large Cap
- Abbott Labs (ABT)
- AbbVie (ABBV)
- Alexion Pharmaceuticals (ALXN)
- Allergan (AGN)
- Amgen (AMGN)
- Astellas (4503:JP)
- Biogen (BIIB)
- BioMarin(BMRN)
- Boston Scientific (BSX)
- Bristol Myers (BMY)
- Celgene (CELG)
- CSL Ltd (CSL:AU)
- Daiichi Sankyo (4568.T)
- Dexcom (DXCM)
- Gilead (GILD)
- GlaxoSmithKline (GSK)
- Incyte (INCY)
- Ipsen SA (IPSEY)
- Jazz (JAZZ)
- Medtronic (MDT)
- Mylan N.V. (MYL)
- Regeneron (REGN)
- Sanofi (SNY)
- Teva Pharmaceuticals (TEVA)
- Vertex (VRTX)
- Zimmer Biomet (ZBH)
Mid Cap
- Acadia Pharmaceuticals (ACAD)
- Acceleron (XLRN)
- Alkermes (ALKS)
- Allogene Therapeutics (ALLO)
- Alnylam (ALNY)
- Amarin Corporation (AMRN)
- Arena Pharmaceuticals (ARNA)
- argenx (ARGX)
- Array (ARRY)
- Ascendis (ASND)
- bluebird bio (BLUE)
- Dynavax Technologies (DVAX)
- Evotec AG (EVT.DE)
- Galapagos NV (GLPG)
- Global Blood Therapeutics (GBT)
- GW Pharmaceuticals (GWPH)
- Halozyme Therapeutics (HALO)
- Immunomedics Inc (IMMU)
- Intercept Pharmaceutical (ICPT)
- Lee's Pharmaceutical Holdings (0950.HK)
- Moderna Therapeutics (MRNA)
- Morphosys AG (MOR)
- Nektar Therapeutics (NKTR)
- Neurocrine Biosciences (NBIX)
- Novocure (NVCR)
- Sage Therapeutics (SAGE)
- Santen (SZD.F)
- Sarepta (SRPT)
- Seattle Genetics (SGEN)
- United Therapeutics (UTHR)
Small Cap/Private
- Acorda Therapeutics (ACOR)
- Alder Biotherapeutics (ALDR)
- AMAG Pharmaceuticals (AMAG)
- Amicus Therapeutics (FOLD)
- AnaptysBio (ANAB)
- Coherus Biosciences (CHRS)
- Five Prime Therapeutics (FPRX)
- Idera Pharmaceuticals (IDRA)
- ImmunoGen (IMGN)
- Insys Therapeutics (INYS)
- Intra-Cellular Therapies (ITCI)
- Ironwood Pharmaceuticals (IRWD)
- Karyopharm (KPTI)
- Mallinckrodt (MNK)
- Molecular Partners AG (MOLN.SW)
- MyoKardia (MYOK)
- PTC Therapeutics (PTCT)
- Replimune (REPL)
- Rubius Therapeutics (RUBY)
- Sangamo Therapeutics (SGMO)
- Sienna Biopharmaceuticals (SNNA)
- Solid Biosciences (SLDB)
- Supernus Pharmaceuticals (SUPN)
- TG Therapeutics (TGTX)
- Tricida (TCDA)
- Urogen Pharmaceuticals (URGN)
- Y-mAbs Therapeutics (YMAB)
- Ziopharm Oncology (ZIOP)
Micro Cap/Private
- Adverum Biotechnologies (ADVM)
- Axovant Sciences (AXON)
- Basilea Pharmaeuticals (BSLN.SW)
- FLX Bio
- Kala Pharmaceuticals (KALA)
- ORIC Pharmaceuticals
- Springworks
For the full report, please download the PDF version.
For our disclosures, please read the Biomedtracker Research Standards.